Clinical study of insulin detemir combined with repaglinide in the treatment of type 2 diabetes
10.13699/j.cnki.1001-6821.2015.05.003
- VernacularTitle:地特胰岛素联合瑞格列奈治疗2型糖尿病的临床对照研究
- Author:
Kai-Ping LIU
1
;
Guo-Qing SHEN
;
Xiao-Fang ZHOU
;
Hai-Gang CAI
;
Li ZHU
;
Hong-Mei QIU
;
Wei LI
;
Ji-Yu YAO
;
Chun-Xian CHEN
;
Xu-Lan YANG
Author Information
1. 玉溪市人民医院 内分泌科
- Keywords:
type 2 diabetes;
insulin detemir;
repaglinide;
insulin aspart 30;
clinical study
- From:
The Chinese Journal of Clinical Pharmacology
2015;(5):330-332
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of insulin det-emir combined with repaglinide on the treatment of type 2 diabetes.Methods Eighty five cases with type 2 diabetes and not responsive to more than two abtidiabetic drugs were recruited in this study, and then were randomized divided into the experiment group ( n=41 ) and control group ( n=44 ).Patients in the experiment group were given treatment of insulin detemir 0.1 U· kg -1 through hypodermic injection at 22∶00 com-bined with repaglinide 0.5-1.0 mg 15 minutes before three meals, and those in the control group were treated with insulin aspart 30, 0.5-1.0 U· kg-1 through hypodermic injection 10 minutes before breakfast and dinner.The treatment lasted for three months.The data of fasting plasma-glucose ( FPG ) , 2 -hour postprandial plasma glucose ( 2 h PG ) , hemoglobin A1C ( HbA1C ) and so on were recorded and compared between the two groups.Results The serum level of FPG, 2 h PG and HbA1C were significantly decreased in the two groups after treatment ( P<0.05) , and glucose level in the experiment group was stabler than the control group.Levels of fasting blood -glucose C peptide and 2 -hour postprandial blood-glucose C peptide were statistically decreased in the both groups(P<0.05), with a more significant decrease found in experiment group(P<0.05).The risk to devel-op glucopenia was much higher in the control group than that in the experiment group( P<0.05).Conclusion Insu-lin detemir combined with repaglinide can significantly decrease the serum level of glucose in patients with type 2 diabe-tes with low risk to develop glucopenia.
